6-(1-pyrrolyl)-9-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)purine | 402724-66-7

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 6-(1-pyrrolyl)-9-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)purine
• 英文别名: 6-(1-pyrrolyl)-9-(2,3,5-tri-O-benzoyl-beta-L-ribofuranosyl)purine；[(2S,3S,4S,5S)-3,4-dibenzoyloxy-5-(6-pyrrol-1-ylpurin-9-yl)oxolan-2-yl]methyl benzoate
• CAS: 402724-66-7
• 化学式: C₃₅H₂₇N₅O₇
• 分子量: 629.629
• InChiKey: BXWJIIBZPRBTQO-KDWIKIOXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  47
• 可旋转键数：
  12
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  137
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  6-(1-pyrrolyl)-9-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)purine 、 氨 在 水 、 乙醚 、 Sodium sulfate-III 、 silica gel 作用下， 以 tetrahydrofuran methanol 为溶剂， 反应 2.0h， 以to give 0.12 g of 6-(1-pyrrolyl)-9-(β-L-ribofuranosyl)purine as a white solid of melting point 114-115° C.的产率得到6-(1-pyrrolyl)-9-(β-L-ribofuranosyl)purine
  参考文献：
  名称：

  Anti-HCV nucleoside derivatives

  摘要：

  本发明包括新颖和已知的嘌呤和嘧啶核苷衍生物，已发现对丙型肝炎病毒（HCV）具有活性。本发明声明了使用这些衍生物治疗HCV感染，以及披露的新颖核苷衍生物。

  公开号：

  US20030008841A1
• 作为产物：
  描述：

  6-(1H-pyrrol-1-yl)-1H-purine 、 1-乙酰氧基-2,3,5-三苯甲酰氧基-β-L-呋喃核糖 、 N-甲基-N-(三甲基硅烷基)三氟乙酰胺 、 三氟甲磺酸三甲基硅酯 在 碳酸氢钠 、 Sodium sulfate-III 、 silica gel 作用下， 以 1,2-二氯乙烷 、 二氯甲烷 为溶剂， 反应 16.0h， 以to give 0.56 g of 6-(1-pyrrolyl)-9-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)purine as a white solid的产率得到6-(1-pyrrolyl)-9-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)purine
  参考文献：
  名称：

  Anti-HCV nucleoside derivatives

  摘要：

  本发明包括新颖和已知的嘌呤和嘧啶核苷衍生物，已发现对丙型肝炎病毒（HCV）具有活性。本发明声明了使用这些衍生物治疗HCV感染，以及披露的新颖核苷衍生物。

  公开号：

  US20030008841A1

文献信息

• NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1315736A2

  公开（公告）日：2003-06-04
• [EN] NUCLEOSIDE DERIVATIVES<br/>[FR] DERIVES DE NUCLEOSIDES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002018404A2

  公开（公告）日：2002-03-07

  Use of compounds of formula (I), wherein R1 is hydrogen, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyano, isocyano or azido; R2 is hydrogen, hydroxy, alkoxy, chlorine, bromine or iodine; R3 is hydrogen; or R?2 and R3¿ together represent =CH¿2?; or R?2 and R3¿ represent fluorine; X is O, s or CH¿2?; a, b, c, d denoting asymmetric carbon atoms each of which is substituted with 4 different substituents; and B signifies a purine base B1 which is connected through the 9-nitrogen of formula (B1), wherein R?4¿ is hydrogen, hydroxyl, alkyl, alkoxy, alkylthio, aryloxy, arylthio, heterocyclyl, NR7R8, halogen or SH; R5 is hydrogen, hydroxy, alkyl, haloalkyl, cycloalkyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, heterocyclyl, heterocyclylamino, halogen, NR?7R8, NHOR9, NHNR7R8¿ or SH; R6 is hydrogen, hydroxy, alkyl, alkoxy, alkylthio, aryloxy, arylthio, heterocyclyl, NR7R8, halogen, SH or cyano; R?7 and R8¿ are independently of each other hydrogen, alkyl, aryl, hydroxyalkyl, alkenylalkyl, alkynylalkyl, cycloalkyl or acyl; R9 is hydrogen, alkyl or aryl; or B signifies an oxidised purine base B2 which is connected through the 9-nitrogen of formula (B2), wherein R?4, R5 and R6¿ are as defined above; or B signifies a purine base B3 which is connected through the 9-nitrogen of formula (B3), wherein R?4 and R6¿ are as defined above; R10 is hydrogen, alkyl or aryl; Y is O, S or NR11; R11 is hydrogen, hydroxy, alkyl, OR9, heterocyclyl or NR?7R8; R7, R8 and R9¿ are as defined above; or B signifies a pyrimidine base B4 which is connected through the 1-nitrogen of formula (B4), wherein Z is O or S; R12 is hydrogen, hydroxy, alkyl, alkoxy, haloalkyl, alkylthio, aryl, aryloxy, arylthio, heterocyclyl, heterocyclylamino, halogen, NR?7R8, NHOR9, NHNR7R8¿ or SH; R13 is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, cycloalkyl or halogen; R?7, R8 and R9¿ are as defined above; or B signifies a pyrimidine base B5 which is connected through the 1-nitrogen of formula (B5), wherein Y, Z, R10 are as defined above for the treatment of diseases mediated by the Hepatitis C Virus (HIV) or for the preparation of a medicament for such treatment. The invention is concerned with novel and known purine and pyrimidine nucleoside derivatives, their use as inhibitors of subgenomic Hepatitis C Virus (HCV) RNA replication and pharmaceutical compositions of such compounds.